Peptomyc — Grant · €2.5M

Grant half of a €5M blended EIC Accelerator (Horizon Europe) award for a Phase 1b trial of OMO-103 in first-line metastatic pancreatic cancer. The other half, €2.5M of equity from the EIC Fund, is not reported here; the EIC Fund invested in the 2026 round.

Lead not disclosed RoundGrant Announced31 Oct 2023Not counted in totals CityBarcelona SectorBiotechSource

Something wrong? Suggest a correction →

The company

Peptomyc

peptomyc.com

Now Series A Barcelona

Investors 1

European Innovation Council (EIC Accelerator)